| Antitope Limited, UK. Announces Antibody Research Agreement with ARIUS Research, Inc |
|
Antitope Limited, UK. Announces Antibody Research Agreement with ARIUS Research, Inc. - 10th January 2007. Antitope Ltd., a leader in the development of Composite Human Antibody technology for the generation of therapeutic antibodies, announced a research agreement with ARIUS Research, Inc. ("ARIUS" or the "Company") (TSX: ARI). Under the research contract, Antitope will engineer humanized monoclonal antibodies from ARIUS' mouse versions against a selection of cancer targets identified by ARIUS using their FunctionFIRST™ platform. The ability to "humanize" antibodies has been a key development in their success as drug treatments for human disease. "We are extremely pleased to be working with ARIUS to produce humanized antibodies for their novel targets for cancer" said Dr Matthew Baker, Chief Scientific Officer and founder of Antitope Limited. "This collaboration provides an excellent opportunity for Antitope to use its extensive expertise in the area of antibody humanization to assist ARIUS in developing new therapies for treatment of a range of cancers." "The expertise at Antitope is an excellent fit with ARIUS' in-house antibody engineering group," said Dr. Susan Hahn, Director of Development, "The combined efforts of our companies will help expedite development of clinical molecules as ARIUS moves toward trials in patients." About Antitope Antitope Ltd. is a Cambridge UK-based biotechnology company specializing in immunogenicity testing and the engineering of therapeutic antibodies/proteins to reduce immunogenicity. Antitope's proprietary Composite Human Antibody technology builds upon the previous pioneering work of its founders in the detection and removal of T cell epitopes in antibodies/proteins through humanization and de-immunisation technologies. Antitope are a privately-held company and have established multiple commercial relationships with leading biotechnology and pharmaceutical companies. For further information on Antitope visit http://www.antitope.co.uk/. About ARIUS Research ARIUS Research Inc. is a biotechnology company dedicated to personalizing cancer therapy through the discovery and development of novel anticancer monoclonal antibodies (MAbs). Established in 1999, ARIUS has built a proprietary technology platform, FunctionFIRST™, that rapidly identifies powerful MAbs targeting a variety of cancer indications. This antibody generation engine has enabled ARIUS to assemble a growing pipeline, which is used for commercial collaborations and in-house development. ARIUS has ongoing partnerships with key biotechnology and drug development companies. The Company is listed on the TSX under the symbol "ARI".For further information, visit http://www.ariusresearch.com/ |